EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
EyePoint Pharmaceuticals (NASDAQ:EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Dr. Jay S. Duker, President and CEO, will engage in a fireside chat on August 13, 2025, at 10:00 a.m. ET.
Investors can access the live webcast through the company's website, with a replay available for 90 days following the event.
EyePoint Pharmaceuticals (NASDAQ:EYPT), un'azienda specializzata nello sviluppo di terapie per gravi malattie retiniche, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright, giunta alla quinta edizione. Il dott. Jay S. Duker, Presidente e CEO, parteciperà a una conversazione informale il 13 agosto 2025 alle 10:00 ET.
Gli investitori potranno seguire la diretta streaming tramite il sito web dell'azienda, con la possibilità di rivedere l'evento per 90 giorni dopo la sua conclusione.
EyePoint Pharmaceuticals (NASDAQ:EYPT), una empresa dedicada al desarrollo de terapias para enfermedades retinianas graves, ha anunciado su participación en la próxima Conferencia Virtual Anual de Oftalmología H.C. Wainwright, en su quinta edición. El Dr. Jay S. Duker, Presidente y CEO, participará en una charla informal el 13 de agosto de 2025 a las 10:00 a.m. ET.
Los inversores podrán acceder a la transmisión en vivo a través del sitio web de la compañía, con una repetición disponible durante 90 días después del evento.
EyePoint Pharmaceuticals (NASDAQ:EYPT)는 중증 망막 질환 치료제 개발에 주력하는 회사로, 다가오는 H.C. Wainwright 제5회 연례 안과 가상 콘퍼런스에 참여한다고 발표했습니다. Jay S. Duker 박사, 사장 겸 CEO가 2025년 8월 13일 오전 10시(동부시간)에 파이어사이드 채팅에 참여할 예정입니다.
투자자들은 회사 웹사이트를 통해 생중계에 접속할 수 있으며, 행사 종료 후 90일 동안 다시보기가 제공됩니다.
EyePoint Pharmaceuticals (NASDAQ:EYPT), une société spécialisée dans le développement de traitements pour les maladies rétiniennes graves, a annoncé sa participation à la prochaine 5e conférence virtuelle annuelle d'ophtalmologie H.C. Wainwright. Dr Jay S. Duker, président et CEO, participera à une discussion informelle le 13 août 2025 à 10h00 ET.
Les investisseurs pourront accéder à la diffusion en direct via le site web de la société, avec une rediffusion disponible pendant 90 jours après l'événement.
EyePoint Pharmaceuticals (NASDAQ:EYPT), ein Unternehmen, das sich auf die Entwicklung von Therapeutika für schwere Netzhauterkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden 5. jährlichen virtuellen Ophthalmologie-Konferenz von H.C. Wainwright angekündigt. Dr. Jay S. Duker, Präsident und CEO, wird am 13. August 2025 um 10:00 Uhr ET an einem Kamin-Gespräch teilnehmen.
Investoren können den Live-Webcast über die Website des Unternehmens verfolgen, wobei eine Wiederholung für 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Thursday, August 13, 2025 at 10:00 a.m. ET.
A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When is EyePoint Pharmaceuticals (EYPT) presenting at the H.C. Wainwright Ophthalmology Conference?
How can investors access EyePoint's (EYPT) presentation at the H.C. Wainwright conference?
Who will be presenting for EyePoint Pharmaceuticals at the H.C. Wainwright conference?
What type of company is EyePoint Pharmaceuticals (EYPT)?
